An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

EFFECT OF CALCIPOTRIOL PLUS BETAMETHASONE DIPROPIONATE GEL ON THE HPA AXIS AND CALCIUM METABOLISM IN ADOLESCENT SUBJECTS (AGED 12 TO 16 YEARS, 11 MONTHS) WITH SCALP AND BODY PSORIASIS.

Intervention/treatment:
LEO 80185
Medical condition:
SCALP AND BODY PSORIASIS
Protocol code:
LP0076-1017
Control number:
171087
Status:
Closed
Approved:
February 07, 2014
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT02038569
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
12 Years to 17 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Clinical Disclosure Specialist
Organization
LEO Pharma A/S
Phone:
+45 44945888
Sponsor
LEO PHARMA AS

Locations

Manitoba

Winnipeg Clinic
Winnipeg, Manitoba, R3C 0N2

Newfoundland and Labrador

Adult, Pediatric and Laser Derma
St. John's, Newfoundland and Labrador, A1A 4Y3

Ontario

Lynderm Research Inc.
Markham, Ontario, L3P 1A8
Skin Centre for Dermatology
Peterborough, Ontario, K9J 1Z2

Results

See the results from the trial NCT02038569. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?